Abstract
Prostate-specific antigen (PSA) has been criticized for its low specificity for prostate cancer, which has led to the increased adoption of additional biomarkers, PSA density (PSAD), and multiparametric magnetic resonance imaging (mpMRI) to increase the localization, risk stratification, and diagnosis of prostate cancer [...].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
